The Biology of CEAS and Its Mimics

While many bowel diseases are caused by an overactive immune system attacking the gut, chronic enteropathy associated with SLCO2A1 (CEAS) is fundamentally a biological “transport” problem ^[1][2]. It occurs because of a specific genetic glitch that prevents your body from properly managing prostaglandins—lipid mediators that help regulate blood flow and protect the lining of your intestines ^[3][4].

Understanding the biology of CEAS helps explain why it doesn’t always behave like other intestinal conditions and why treatments that work for more common diseases often fail to help.

The Role of the SLCO2A1 Gene

The SLCO2A1 gene provides the blueprint for a protein called OATP2A1 (also known as the prostaglandin transporter or PGT) ^[3][5]. Think of this protein as a transporter: its job is to move prostaglandins from the space outside your cells to the inside, where they can be broken down and cleared away ^[3][4].

In people with CEAS, both copies of the SLCO2A1 gene have pathogenic variants, meaning this transport system is impaired or missing from the blood vessels and lining of the small intestine ^[1][5]. Because the prostaglandins (specifically one called PGE2) cannot be handled properly, they accumulate in the tissue. This dysregulation is thought to make the lining of the small intestine vulnerable, contributing to mucosal injury and the formation of multiple shallow ulcers that leak blood and protein ^[1][2].

CEAS vs. Crohn’s Disease: The Great Mimic

For years, CEAS was frequently mistaken for Crohn’s disease because both cause ulcers in the small bowel ^[2]. However, they are biologically distinct:

• Inflammatory Markers: In Crohn’s disease, the body is in a state of high inflammation, usually resulting in a high C-reactive protein (CRP) level in the blood ^[6][7]. In CEAS, your CRP level is often near-normal or very low, even if you are feeling quite ill ^[8][6]. Note: this is a clue, not proof; CRP can be normal in some Crohn’s patients, and high in CEAS if an infection occurs.
• Ulcer Shape: On an endoscopy, Crohn’s ulcers are often “longitudinal” (long and deep) or look like “cobblestones” ^[9][2]. CEAS ulcers are typically shallow and “circular” or “eccentric,” meaning they wrap around the inner circumference of the intestine ^[6][10].
• Treatment Response: Because Crohn’s is an immune-driven disease, it usually responds to steroids or biological drugs (like anti-TNF therapy) ^[11]. Because CEAS is a genetic transport problem, these medications often have limited or inconsistent benefit ^[12][13].

Other Biological Mimics

Doctors must also distinguish CEAS from other conditions that cause small bowel ulcers:

• NSAID-Induced Enteropathy: Common pain relievers like ibuprofen or naproxen (NSAIDs) can cause small bowel ulcers ^[10]. While both CEAS and NSAID-related damage involve prostaglandins, the mechanism is different. NSAIDs stop the production of protective prostaglandins, while CEAS is a genetic defect in how they are transported ^[3][10]. Patient Action: Ask your prescriber before using over-the-counter NSAIDs like ibuprofen, but do not stop taking prescribed low-dose aspirin for cardiovascular reasons without speaking to your doctor first.
• CMUSE (Chronic Multifocal Ulcerative Stenosing Enteritis): This is another rare genetic condition similar to CEAS, but it is caused by a mutation in a different gene (PLA2G4A) ^[14]. It typically causes ulcers in the upper part of the small intestine (the jejunum) ^[14].
• Intestinal Tuberculosis (TB): In certain parts of the world, TB can infect the gut and cause ulcers ^[9]. Unlike CEAS, TB is an infection and can be identified through biopsies that look for specific bacteria or characteristic “granulomas” under a microscope ^[9][15].

The Clue in the Urine: PGE-MUM Testing

Before undergoing expensive or complex genetic testing, doctors can use a simple urine test to look for an adjunct biomarker of CEAS called PGE-MUM ^[7].

Because the pathway for prostaglandins is impaired in CEAS, the byproduct of these prostaglandins builds up and is excreted in the urine ^[7]. Research in specific study populations has shown that patients with CEAS often have significantly higher levels of PGE-MUM compared to those with Crohn’s disease ^[7]. While one study found a level above approximately 48.9 μg/g·creatinine to be a helpful threshold, this cutoff is highly assay- and study-specific ^[7]. It is an adjunct tool rather than a stand-alone diagnostic replacement for genetic testing ^[8][2].